OBSOLETE: Genetic cerebrovascular dementia

Genetic cerebrovascular dementia refers to a group of inherited conditions where changes in the blood vessels of the brain lead to reduced blood flow, small strokes, or damage to brain tissue over time. This ultimately causes a decline in thinking, memory, and other mental abilities — a process known as dementia. The term 'genetic cerebrovascular dementia' has been marked as obsolete in medical classification systems because it was considered too broad. Today, doctors prefer to use more specific diagnoses such as CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), CARASIL, or other named hereditary small vessel diseases of the brain. Symptoms typically develop in adulthood and may include recurrent strokes or mini-strokes, progressive memory loss, difficulty with planning and decision-making, mood changes such as depression, and migraine headaches (sometimes with visual disturbances called aura). Over time, walking and balance problems may develop, and affected individuals may become increasingly dependent on others for daily activities. Treatment is mainly supportive, as there is currently no cure for these conditions. Management focuses on controlling stroke risk factors such as high blood pressure, preventing blood clots, treating depression, and providing rehabilitation services. Genetic counseling is important for affected families. Because this term is now obsolete, patients are encouraged to seek a more specific genetic diagnosis, which can guide treatment and family planning decisions more effectively.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

Bring these to your next appointment

• Q1.What specific genetic condition is causing my symptoms, and has genetic testing confirmed the diagnosis?,What can I expect as this disease progresses, and how quickly might changes happen?,Are there any clinical trials or new treatments I should know about?,What steps can I take to reduce my risk of future strokes?,Should my family members be tested for this genetic condition?,What support services are available to help me and my family cope with this diagnosis?,Are there any medications or activities I should avoid because of this condition?

Common questions about OBSOLETE: Genetic cerebrovascular dementia